<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of neonatal cholestasis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of neonatal cholestasis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Causes of neonatal cholestasis</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Obstruction</td> </tr> <tr> <td class="indent1"> <ul> <li>Biliary atresia<sup>¶</sup></li> <li>Biliary cysts</li> <li>Inspissated bile/mucous plug</li> <li>Cholelithiasis or biliary sludge</li> <li>Tumors/masses (intrinsic and extrinsic to the bile duct)</li> <li>Neonatal sclerosing cholangitis (<a href="https://www.omim.org/entry/617394" target="_blank">MIM #617394</a>)<sup>[1]</sup></li> <li>Spontaneous perforation of the bile ducts</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Infection<sup>¶</sup></td> </tr> <tr> <td class="indent1"><strong>Viral</strong> <ul class="decimal_heading"> <li>Adenovirus, cytomegalovirus, echovirus, enterovirus, herpes simplex virus, HIV, parvovirus B19, rubella</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Bacterial</strong> <ul class="decimal_heading"> <li>Urinary tract infection, sepsis, syphilis</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Protozoal</strong> <ul class="decimal_heading"> <li>Toxoplasma</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Genetic/metabolic disorders</td> </tr> <tr> <td class="indent1"><strong>Inherited cholestatic disorders</strong> <ul class="decimal_heading"> <li>Alagille syndrome<sup>¶</sup><sup>Δ</sup> (<a href="https://omim.org/entry/118450" target="_blank">MIM #118450</a>)</li> <li>Alpha-1 antitrypsin deficiency (PI*Z homozygotes or PI*SZ heterozygotes)<sup>¶</sup> (<a href="https://omim.org/entry/613490" target="_blank">MIM #613490</a>)</li> <li>ARC syndrome (arthrogryposis-renal dysfunction-cholestasis) (<a href="https://omim.org/entry/208085" target="_blank">MIM #208085</a>)</li> <li>Cystic fibrosis (<a href="https://omim.org/entry/219700" target="_blank">MIM #219700</a>)</li> <li>Progressive familial intrahepatic cholestasis (types 1 to 5)<sup>¶</sup><sup>◊</sup> (<a href="https://omim.org/entry/211600" target="_blank">MIM #211600</a>, <a href="https://omim.org/entry/601847" target="_blank">MIM #601847</a>, <a href="https://omim.org/entry/602347" target="_blank">MIM #602347</a>, <a href="https://omim.org/entry/615878" target="_blank">MIM #615878</a>, <a href="https://www.omim.org/entry/617049" target="_blank">MIM #617049</a>)</li> <li><em>MYO5B</em> gene mutations (with or without congenital diarrhea due to microvillus inclusion disease)<sup>[2]</sup> (<a href="https://omim.org/entry/251850" target="_blank">MIM #251850</a>, <a href="https://www.omim.org/entry/619868" target="_blank">MIM #619868</a>)</li> <li>NISCH syndrome (neonatal ichthyosis sclerosing cholangitis) (<a href="https://omim.org/entry/607626" target="_blank">MIM #607626</a>)</li> <li>Dubin-Johnson syndrome<sup>§</sup><sup>[3]</sup> (<a href="https://omim.org/entry/237500" target="_blank">MIM #237500</a>)</li> <li>Rotor syndrome (<a href="https://www.omim.org/entry/237450" target="_blank">MIM #237450</a>)</li> <li>Aagenaes syndrome (<a href="https://www.omim.org/entry/214900" target="_blank">MIM %214900</a>)<sup>[4]</sup></li> <li><em>USP53</em> gene mutations (<a href="https://www.omim.org/entry/619658" target="_blank">MIM #619658</a>)<sup>[5]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Disorders of carbohydrate metabolism</strong> <ul class="decimal_heading"> <li>Galactosemia<sup>¶</sup> (<a href="https://omim.org/entry/230400" target="_blank">MIM #230400</a>)</li> <li>Fructosemia (<a href="https://omim.org/entry/229600" target="_blank">MIM #229600</a>)</li> <li>Glycogen storage disease type IV (<a href="https://omim.org/entry/232500" target="_blank">MIM #232500</a>)</li> <li>Transaldolase deficiency (<a href="https://www.omim.org/entry/606003" target="_blank">MIM #606003</a>)<sup>[6]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Disorders of amino acid metabolism</strong> <ul class="decimal_heading"> <li>Tyrosinemia (type 1)<sup>¶</sup> (<a href="https://omim.org/entry/276700" target="_blank">MIM #276700</a>)</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Disorders of lipid metabolism</strong> <ul class="decimal_heading"> <li>Lysosomal acid lipase deficiency (Wolman disease) (<a href="https://omim.org/entry/278000" target="_blank">MIM #278000</a>), Niemann-Pick type C (<a href="https://omim.org/entry/257220" target="_blank">MIM #257220</a>), Gaucher type 2 (<a href="https://omim.org/entry/230900" target="_blank">MIM #230900</a>)</li> <li>Fatty acid oxidation defects (eg, <a href="https://www.omim.org/entry/201470" target="_blank">MIM #201470</a>, <a href="https://www.omim.org/entry/201475" target="_blank">MIM #201475</a>)</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Disorders of bile acid synthesis</strong> <ul class="decimal_heading"> <li>Bile acid synthesis defects (types 1 to 6) (<a href="https://www.omim.org/entry/607765" target="_blank">MIM #607765</a>, <a href="https://www.omim.org/entry/235555" target="_blank">MIM #235555</a>, <a href="https://www.omim.org/entry/613812" target="_blank">MIM #613812</a>, <a href="https://www.omim.org/entry/214950" target="_blank">MIM #214950</a>, <a href="https://www.omim.org/entry/616278" target="_blank">MIM #616278</a>, <a href="https://www.omim.org/entry/617308" target="_blank">MIM #617308</a>)</li> <li>Cerebrotendinous xanthomatosis (<a href="https://www.omim.org/entry/213700" target="_blank">MIM #213700</a>)</li> <li>Amidation defects (<a href="https://www.omim.org/entry/602938" target="_blank"><em>BAAT</em></a> or <a href="https://www.omim.org/entry/603314" target="_blank"><em>SLC27A5</em></a> gene mutations)</li> <li>Zellweger spectrum disorders<sup>◊</sup> (<a href="https://omim.org/entry/214100" target="_blank">MIM #214100</a> and others)</li> <li>Smith-Lemli-Opitz syndrome<sup>◊</sup> (<a href="https://omim.org/entry/270400" target="_blank">MIM #270400</a>)</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Mitochondrial disorders</strong><sup>¥</sup></td> </tr> <tr> <td class="indent1"><strong>Urea cycle defect</strong> <ul class="decimal_heading"> <li>Citrin deficiency (type II) (<a href="https://omim.org/entry/605814" target="_blank">MIM #605814</a>)</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Congenital disorders of glycosylation</strong> <ul class="decimal_heading"> <li>Phosphomannomutase 2 deficiency (<a href="https://www.omim.org/entry/212065" target="_blank">MIM #212065</a>)</li> <li>Phosphoglucomutase 1 deficiency (<a href="https://www.omim.org/entry/614921" target="_blank">MIM #614921</a>)</li> <li>Mannosephosphate isomerase deficiency (<a href="https://www.omim.org/entry/602579" target="_blank">MIM #602579</a>)</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Alloimmune</td> </tr> <tr> <td class="indent1"> <ul> <li>Gestational alloimmune liver disease</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Toxic</td> </tr> <tr> <td class="indent1"> <ul> <li>Intestinal failure-associated liver disease (parenteral nutrition)<sup>¶</sup></li> <li>Drugs (ceftriaxone, erythromycin, sulfa-containing medications)</li> </ul> </td> </tr> <tr> </tr> <tr> <td class="subtitle1_single">Miscellaneous</td> </tr> <tr> <td class="indent1"> <ul> <li>"Idiopathic" neonatal hepatitis</li> <li>Nonsyndromic paucity of the interlobular bile ducts</li> <li>Hemophagocytic lymphohistiocytosis</li> <li>Shock/hypoperfusion</li> <li>Intestinal obstruction</li> <li>Congenital portosystemic shunt</li> <li>Hypothyroidism</li> <li>Hypopituitarism (eg, in septo-optic dysplasia)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes disorders in which cholestasis can be a prominent feature in the neonatal period. For disorders that present with hepatic failure, refer to UpToDate content on acute hepatic failure in infants and children.</div><div class="graphic_footnotes"><p>HIV: human immunodeficiency virus.</p>
<p>¶ More common disorders causing neonatal cholestasis.</p>
<p>Δ Alagille syndrome is also known as syndromic paucity of the interlobular bile ducts or arteriohepatic dysplasia.</p>
<p>◊ These disorders are classified as secondary bile acid metabolic defects.</p>
<p>§ Presentation of Dubin-Johnson syndrome in neonates and young infants is rare but has been reported<sup>[3]</sup>.</p>
¥ For mitochondrial hepatopathies, refer to UpToDate table and content on acute liver failure in infants and children.</div><div class="graphic_reference">References:
<ol>
<li>Grammatikopoulos T, Sambrotta M, Strautnieks S, et al. Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis. J Hepatol 2016; 65:1179.</li>
<li>Cockar I, Foskett P, Strautnieks S, et al. Mutations in Myosin 5B in Children With Early-onset Cholestasis. J Pediatr Gastroenterol Nutr 2020; 71:184.</li>
<li>Towaga T, Mizuochi T, Sugiura T, et al. Clinical, Pathologic, and Genetic Features of Neonatal Dubin-Johnson Syndrome: A Multicenter Study in Japan. J Pediatr 2018; 196:161.</li>
<li>Almaas R, Atneosen-Åsegg M, Ytre-Arne ME, et al. Aagenaes syndrome/lymphedema cholestasis syndrome 1 is caused by a founder variant in the 5'-untranslated region of UNC45A. J Hepatol 2023; S0168-8278(23)00410-5.</li>
<li>Bull LN, Ellmers R, Foskett P, et al. Cholestasis Due to USP53 Deficiency. J Pediatr Gastroenterol Nutr 2021; 72:667.</li>
<li>Grammatikopoulos T, Hadzic N, Foskett P, et al. Liver Disease and Risk of Hepatocellular Carcinoma in Children With Mutations in TALDO1. Hepatol Commun; 6:473.</li>
</ol></div><div id="graphicVersion">Graphic 64995 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
